Lucid Non Current Assets Total from 2010 to 2024

LUCD Stock  USD 0.74  0  0.14%   
Lucid Diagnostics' Non Current Assets Total are increasing over the years with slightly volatile fluctuation. Non Current Assets Total are expected to dwindle to about 3.6 M. Non Current Assets Total is the total value of a company's long-term assets, which are not expected to be converted into cash or used up within one year or the operating cycle, including property, plant, and equipment, and intangible assets. View All Fundamentals
 
Non Current Assets Total  
First Reported
2010-12-31
Previous Quarter
5.2 M
Current Value
3.6 M
Quarterly Volatility
2.2 M
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check Lucid Diagnostics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Lucid Diagnostics' main balance sheet or income statement drivers, such as Interest Expense of 436.8 K, Tax Provision of 0.0 or Depreciation And Amortization of 2.7 M, as well as many indicators such as Price To Sales Ratio of 23.04, Dividend Yield of 0.0 or Days Sales Outstanding of 12.77. Lucid financial statements analysis is a perfect complement when working with Lucid Diagnostics Valuation or Volatility modules.
  
Check out the analysis of Lucid Diagnostics Correlation against competitors.
For information on how to trade Lucid Stock refer to our How to Trade Lucid Stock guide.

Latest Lucid Diagnostics' Non Current Assets Total Growth Pattern

Below is the plot of the Non Current Assets Total of Lucid Diagnostics over the last few years. It is the total value of a company's long-term assets, which are not expected to be converted into cash or used up within one year or the operating cycle, including property, plant, and equipment, and intangible assets. Lucid Diagnostics' Non Current Assets Total historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Lucid Diagnostics' overall financial position and show how it may be relating to other accounts over time.
Non Current Assets Total10 Years Trend
Slightly volatile
   Non Current Assets Total   
       Timeline  

Lucid Non Current Assets Total Regression Statistics

Arithmetic Mean1,723,245
Geometric Mean1,059,251
Coefficient Of Variation129.39
Mean Deviation1,573,059
Median643,000
Standard Deviation2,229,752
Sample Variance5T
Range7.5M
R-Value0.65
Mean Square Error3.1T
R-Squared0.42
Significance0.01
Slope322,303
Total Sum of Squares69.6T

Lucid Non Current Assets Total History

20243.6 M
20235.2 M
20228.2 M
20211.7 M
2020755 K

About Lucid Diagnostics Financial Statements

There are typically three primary documents that fall into the category of financial statements. These documents include Lucid Diagnostics income statement, its balance sheet, and the statement of cash flows. Lucid Diagnostics investors use historical funamental indicators, such as Lucid Diagnostics's Non Current Assets Total, to determine how well the company is positioned to perform in the future. Although Lucid Diagnostics investors may use each financial statement separately, they are all related. The changes in Lucid Diagnostics's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on Lucid Diagnostics's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet, but not equivalent to net income shown on the income statement. We offer a historical overview of the basic patterns found on Lucid Diagnostics Financial Statements. Understanding these patterns can help to make the right decision on long term investment in Lucid Diagnostics. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Non Current Assets Total5.2 M3.6 M

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Additional Information and Resources on Investing in Lucid Stock

When determining whether Lucid Diagnostics is a strong investment it is important to analyze Lucid Diagnostics' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Lucid Diagnostics' future performance. For an informed investment choice regarding Lucid Stock, refer to the following important reports:
Check out the analysis of Lucid Diagnostics Correlation against competitors.
For information on how to trade Lucid Stock refer to our How to Trade Lucid Stock guide.
You can also try the Positions Ratings module to determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance.
Is Health Care Equipment & Supplies space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Lucid Diagnostics. If investors know Lucid will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Lucid Diagnostics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(1.26)
Revenue Per Share
0.07
Quarterly Revenue Growth
1.244
Return On Assets
(0.69)
Return On Equity
(2.56)
The market value of Lucid Diagnostics is measured differently than its book value, which is the value of Lucid that is recorded on the company's balance sheet. Investors also form their own opinion of Lucid Diagnostics' value that differs from its market value or its book value, called intrinsic value, which is Lucid Diagnostics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Lucid Diagnostics' market value can be influenced by many factors that don't directly affect Lucid Diagnostics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Lucid Diagnostics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Lucid Diagnostics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Lucid Diagnostics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.